Our innovations

First Polish carotid stent launched on market

Doctors from the American Heart of Poland in cooperation with BALTON Ltd. have successfully performed the official implantation of the first Polish hybrid carotid stent named “MER” under cerebral protection of Polish vascular filter ROBIN in the patient with advanced heart and vascular disease. Both devices bear the CE marking and have already been authorized on the EU market.

The procedure was performed during scientific conference organized by Polish Professional Association of Interventional Cardiologists and AHP in Ustroń. It was carried out by a team of experts from the American Heart of Poland under the supervision of Professor Paweł Buszman.

The patient, who underwent the official implantation of the first Polish carotid stent, was a 67-year-old male with bilateral carotid arteries stenosis with coexisting heart disease, qualified for aortic valve and coronary artery bypass grafts replacement. An attempt of such complex cardiac surgery treatment without previous dilation of the carotid artery would bring high risk of intraoperative cerebral stroke. Due to the carotid stent implantation we will be able to perform a cardiac surgery within the next 6 weeks.

In many cases, hybrid carotid stent is a better solution than other stents as it fits in the vessel, and at the same time, it covers the atheromatous plaques in a complete and safe way.

The first Polish carotid stents named “MER” are made of a special material with shape memory. Their implantation was conducted in hybrid technology, i.e. close- and open-cell that ensures more effective stabilization of the atheromatous plaques at the stent implantation site, explains Professor Paweł Buszman, the co-founder of the American Heart of Poland.

Hybrid carotid stents underwent preclinical research phase under the leadership of Krzysztof Mielewski, MD, PhD, and Piotr Buszman, MD, PhD, at the Centre for Cardiovascular Research and Development in Kostkowice as well as clinical research phase under the leadership of Przemysław Nowakowski, MD, PhD, at AHP in Chrzanów. At each stage the procedure proved therapeutic effectiveness in all patients.

It is a significant achievement of Polish technology and medicine, and it indicates that the concept of scientific and technical cooperation may become a background for breakthrough solutions in Polish economy,

adds Professor Paweł Buszman.


American Heart of Poland has been engaged for many years in research activities connected with testing of new medical devices and drugs as well as methods of cardiovascular diseases treatment. Our projects enabled the introduction into clinical practice devices such as: first polish coronary stent made of stainless steel 316L “Chopin”, coronary stent made of cobalt chrome alloy “KOS”, first antiproliferative drug eluting stent (coating made of paclitaxel) “Shellak”, thin-strut stent made of cobalt chrome alloy “Coflexus” and coronary stent eluting sirolimus “Alex”. Among the newest projects carried out by our CCRD, the following can be mentioned: program of hybrid myocardial revascularization conducted in patients with advanced multivascular coronary disease, percutaneous mitral valve annuloplasty, aortic valve replacement in aortic valve stenosis for modern self-expanding aortic bioprosthesis 3f Enable by Medtronic (made of equine pericardium), or the first Polish drug-coated balloon catheter (PAX®, Balton Ltd.) used in treatment of vascular diseases.

These solutions have considerably influenced the development of invasive cardiology in Poland - not only have they increased the patients safety and comfort (reduction of complications and repeated revascularizations, reduction of recovery time), but they have also contributed to the improvement of modern technologies accessibility.

Recently published information by the Ministry of health Republic of Poland shows that cardiovascular diseases since more than 50 years still remains the most important cause of death of Polish citizens. Due to the involvement of Polish cardiologists as well as increasing the accessibility of modern medical technologies in the past 10 years the mortality caused by heart attack has significantly decreased. Unfortunately other cardiovascular diseases are still a huge problem.

Przeczytaj także:

Do góry